Lavipharm S.A. — M&A Activity 2026

Apr 9, 2026

Statement for Athens Stock Exchange

Lavipharm to Acquire Prescription Pain Medication Patch in 24 Countries

Peania, Greece – [April 9, 2026]

Lavipharm SA announced today that it has entered into an agreement with Janssen Global Services, LLC to acquire the rights and license trademarks of DUROGESIC®, a prescription pain medication patch, indicated for the management of chronic pain, in 24 countries around the globe.

Under the terms of the agreement, Lavipharm will obtain the relevant marketing authorizations, trademarks, commercialization rights, and manufacturing rights and responsibilities for the product in applicable countries. Lavipharm expects to begin commercializing the product gradually over the coming months following the transfer of the relevant country marketing authorizations or, in applicable markets, when a Lavipharm-manufactured product is approved by local regulatory authorities.

The consideration consists of an upfront payment of $12 million USD.

The transaction will be financed through a combination of new bank debt and equity.

The transaction is expected to have a significant impact on the Group's revenue, with annual sales projected to increase by more than 60%, while export activity—representing the most profitable segment of the Group—is expected to grow by more than 150%.

The completion of the transaction is subject to antitrust approval.

About Lavipharm Lavipharm (ASE: LAVI) is a pharmaceutical company focused on developing and delivering innovative healthcare solutions that advance patient care. Founded in Greece in 1911 and listed on the Athens Stock Exchange since 1995, the company has a strong presence in prescription and over-the-counter medicines in its domestic market. Lavipharm is internationally recognized for its expertise in transdermal drug delivery systems (TDDS) and maintains a global footprint through products distributed worldwide. With more than 115 years of history, Lavipharm remains committed to helping people live longer, healthier lives.

For further Information contact:
Investor Relations
Vasilis Baloumis
Tel: 210 6691 121
Email: ir@lavipharm.com